BioSpace News Archive

Policy

Emmaus Life Sciences Reports Delayed Filing of Annual Report

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.

April 15, 2024
·
3 min read
Microbion Selected to Present at Advanced Wound Care Summit USA

Microbion Corporation today announced that the company has been selected to present topical pravibismane for the treatment of diabetic foot infection (DFI) at the Advanced Wound Care Summit USA held at the Boston Marriot Long Wharf from April 16th to 17th.

April 15, 2024
·
3 min read
Business

Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer

Obsidian Therapeutics, Inc. today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, effective May 1, 2024.

April 15, 2024
·
3 min read
Pharm Country

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd. today announced the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application for UGN-103, a next-generation novel mitomycin-based formulation for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

April 15, 2024
·
7 min read
Drug Development

Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)

Longeveron Inc. today announced that it has been accepted for a Featured Research Oral Presentation to present the Company’s CLEAR MIND Phase 2a study results.

April 15, 2024
·
7 min read
Pharm Country

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)

CorMedix Inc. today announced DefenCath® (taurolidine and heparin) catheter lock solution (CLS) is now commercially available for U.S. inpatient use.

April 15, 2024
·
4 min read
Drug Development

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. announced today it has gained alignment with the U.S. Food and Drug Administration (FDA) on its registrational Phase 3 program for brilaroxazine in schizophrenia.

April 15, 2024
·
7 min read
Business

Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701

Medivir AB announced today that its partner Vetbiolix, a veterinary biotechnology company based in France , reported positive results from a Proof-of-Concept clinical study in periodontal disease in dog with its drug candidate VBX-1000, previously known as MIV-701.

April 15, 2024
·
3 min read
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate

IceCure Medical Ltd. announced today that it has submitted final data to the U.S. Food and Drug Administration (“FDA”) requesting marketing authorization for ProSense® for the indication of treating patients with early stage T1 invasive breast cancer with cryoablation and adjuvant hormone therapy.

April 15, 2024
·
8 min read
Business

Outset Medical Partners with American Nephrology Nurses Association to Support Nephrology Nursing and Patient Care

Outset Medical, Inc. today announced its partnership with the American Nephrology Nurses Association (ANNA) as a member of its new Partnership Advisory Council.

April 15, 2024
·
4 min read